These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 30048994)

  • 21. [Impact of gonadotropin-releasing hormone analogs treatment on final height in girls with central precocious puberty].
    Chen SK; Fan X; Tang Q
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 May; 11(5):374-6. PubMed ID: 19470261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty.
    Lee HS; Yoon JS; Park KJ; Hwang JS
    PLoS One; 2018; 13(8):e0201906. PubMed ID: 30133462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty.
    Swaiss HH; Khawaja NM; Farahid OH; Batieha AM; Ajlouni KM
    Saudi Med J; 2017 Nov; 38(11):1101-1107. PubMed ID: 29114697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of a model for predicting the adult height of girls with idiopathic central precocious puberty.
    Wu W; Zhu X; Chen Y; Yang X; Zhang Y; Chen R
    Eur J Pediatr; 2023 Apr; 182(4):1627-1635. PubMed ID: 36708384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls.
    Houk CP; Kunselman AR; Lee PA
    Pediatrics; 2009 Jun; 123(6):e1059-63. PubMed ID: 19482738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined use of growth hormone and gonadotropin-releasing hormone analogues: the national cooperative growth study experience.
    Kohn B; Julius JR; Blethen SL
    Pediatrics; 1999 Oct; 104(4 Pt 2):1014-8. PubMed ID: 10506254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in Body Mass Index in Girls with Idiopathic Central Precocious Puberty under Gonadotropin-Releasing Hormone Analogue Therapy: The Spanish Registry.
    Corripio R; Soriano-Guillén L; Herrero FJ; Cañete R; Castro-Feijoó L; Escribano A; Espino R; Labarta JI; Argente J
    Horm Res Paediatr; 2016; 86(3):154-160. PubMed ID: 27529349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty.
    Tung YC; Lee JS; Tsai WY; Hsiao PH
    J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the resilience of the girls with central precocious puberty treated with gonadotropin-releasing hormone analog.
    Odabasi Gunes S; Akin O; Eray S
    J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1379-1384. PubMed ID: 34313086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome.
    Chiavaroli V; Liberati M; D'Antonio F; Masuccio F; Capanna R; Verrotti A; Chiarelli F; Mohn A
    Eur J Endocrinol; 2010 Jul; 163(1):55-62. PubMed ID: 20356934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
    Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
    Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Outcomes of Patients with Central Precocious Puberty due to Hypothalamic Hamartoma after GnRHa Treatment: Anthropometric, Metabolic, and Reproductive Aspects.
    Ramos CO; Latronico AC; Cukier P; Macedo DB; Bessa DS; Cunha-Silva M; Arnhold IJ; Mendonca BB; Brito VN
    Neuroendocrinology; 2018; 106(3):203-210. PubMed ID: 28558376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects and significant Adverse Drug Reactions (ADRs) associated with the use of Gonadotropin-Releasing Hormone analogs (GnRHa) for central precocious puberty: a brief review of literature.
    De Sanctis V; Soliman AT; Di Maio S; Soliman N; Elsedfy H
    Acta Biomed; 2019 Sep; 90(3):345-359. PubMed ID: 31580327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum sex hormone-binding globulin levels in healthy children and girls with precocious puberty before and during gonadotropin-releasing hormone agonist treatment.
    Sørensen K; Andersson AM; Skakkebaek NE; Juul A
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3189-96. PubMed ID: 17519314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body mass index evolution and ovarian function in adolescent girls who received GnRH agonist treatment for central precocious puberty or early and fast puberty.
    Buyukyilmaz G; Koca SB; Adiguzel KT; Gurbuz F; Boyraz M
    J Pediatr Endocrinol Metab; 2023 Nov; 36(11):1044-1051. PubMed ID: 37735929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists.
    Jay N; Mansfield MJ; Blizzard RM; Crowley WF; Schoenfeld D; Rhubin L; Boepple PA
    J Clin Endocrinol Metab; 1992 Sep; 75(3):890-4. PubMed ID: 1517382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.
    Antoniazzi F; Bertoldo F; Lauriola S; Sirpresi S; Gasperi E; Zamboni G; Tatò L
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1992-6. PubMed ID: 10372699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The histrelin implant: a novel treatment for central precocious puberty.
    Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
    Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gonadotropin-Releasing Hormone (GnRHa) Therapy for Central Precocious Puberty (CPP): Review of Nuances in Assessment of Height, Hormonal Suppression, Psychosocial Issues, and Weight Gain, with Patient Examples.
    Klein KO; Lee PA
    Pediatr Endocrinol Rev; 2018 Apr; 15(4):298-312. PubMed ID: 29806750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.